Treatment-related myelodysplasia following fludarabine combination chemotherapy

被引：1

作者：

Tam, Constantine S. ^{[1
,2
]}

Seymour, John F. ^{[1
,3
]}

Prince, H. Miles ^{[1
]}

Kenealy, Melita ^{[1
]}

Wolf, Max ^{[1
]}

Januszewicz, E. Henry ^{[1
]}

Westerman, David ^{[1
,4
]}

机构：

[1] Peter MacCallum Canc Ctr, Haematol Dept, Locked Bag 1,ABeckett St, Melbourne, Vic 8006, Australia

[2] Alfred Hosp, Haematol Dept, Melbourne, Australia

[3] Univ Melbourne, Melbourne, Australia

[4] Peter MacCallum Canc Ctr, Pathol Dept, Melbourne, Australia

来源：

HAEMATOLOGICA | 2006年 / 91卷 / 11期

关键词：

purine analog; chemoimmunotherapy; chronic lymphocytic leukemia; follicular lymphoma; Waldenstrom's macroglobulinemia;

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Although myelodysplasia (MDS) and secondary acute myeloid leukemia (sAML) are rare following fludarabine monotherapy, the risk of these diseases may potentially be increased when fludarabine is combined with cyclophosphamide or mitoxantrone due to synergistic effects on the inhibition of DNA repair. Among 137 patients treated with fludarabine combination regimens, ten patients developed MDS/sAML, including one who had received no other therapy. Six patients had abnormalities of chromosomes 5 and/or 7. The crude rate of MDS/sAML was 2.5% for previously untreated patients, and 9.3% for pretreated patients (p=0.28). The rate of MDS/sAML following fludarabine combination therapy is higher than that previously reported for fludarabine monotherapy.

引用

收藏

页码：1546 / 1550

页数：5

相关论文

共 45 条

[21] Prediction of poor outcome in CLL patients following first-line treatment with fludarabine, cyclophosphamide and rituximab [J].

Fink, A. M. ;

Bottcher, S. ;

Ritgen, M. ;

Fischer, K. ;

Pflug, N. ;

Eichhorst, B. ;

Wendtner, C-M ;

Winkler, D. ;

Buhler, A. ;

Zenz, T. ;

Staib, P. ;

Mayer, J. ;

Hensel, M. ;

Hopfinger, G. ;

Wenger, M. ;

Fingerle-Rowson, G. ;

Dohner, H. ;

Kneba, M. ;

Stilgenbauer, S. ;

Busch, R. ;

Hallek, M. .

LEUKEMIA, 2013, 27 (09) :1949-+

[22] US Food and Drug Administration Approval: Rituximab in Combination with Fludarabine and Cyclophosphamide for the Treatment of Patients with Chronic Lymphocytic Leukemia [J].

Casak, Sandra J. ;

Lemery, Steven J. ;

Shen, Yuan Li ;

Rothmann, Mark D. ;

Khandelwal, Aakanksha ;

Zhao, Hong ;

Davis, Gina ;

Jarral, Vaishali ;

Keegan, Patricia ;

Pazdur, Richard .

ONCOLOGIST, 2011, 16 (01) :97-104

[23] Rituximab in combination with high-dose methylprednisolone for the treatment of fludarabine refractory high-risk chronic lymphocytic leukemia [J].

J E Castro ;

J D Sandoval-Sus ;

J Bole ;

L Rassenti ;

T J Kipps .

Leukemia, 2008, 22 :2048-2053

[24] Rituximab in combination with high-dose methylprednisolone for the treatment of fludarabine refractory high-risk chronic lymphocytic leukemia [J].

Castro, J. E. ;

Sandoval-Sus, J. D. ;

Bole, J. ;

Rassenti, L. ;

Kipps, T. J. .

LEUKEMIA, 2008, 22 (11) :2048-2053

[25] Treatment-Related Adverse Events in Extended Stage Small Cell Lung Cancer Patients Receiving First-Line Chemoimmunotherapy Versus Chemotherapy Alone: A Systematic Review and Meta-Analysis [J].

Vitale, Elsa ;

Rizzo, Alessandro ;

Maistrello, Lorenza ;

Guven, Deniz Can ;

Cauli, Omar ;

Galetta, Domenico ;

Longo, Vito .

CANCERS, 2025, 17 (09)

[26] Depression and anxiety in older patients with hematological cancer (70+) - Geriatric, social, cancer- and treatment-related associations [J].

Meier, Cora ;

Taubenheim, Sabine ;

Lordick, Florian ;

Mehnert-Theuerkauf, Anja ;

Goetze, Heide .

JOURNAL OF GERIATRIC ONCOLOGY, 2020, 11 (05) :828-835

[27] Combination therapy with fludarabine and rituximab followed by alemtuzumab in the first-line treatment of patients with chronic lymphocytic leukemia or small lymphocytic lymphoma [J].

Hainsworth, John D. ;

Vazquez, Elizabeth R. ;

Spigel, David R. ;

Raefsky, Eric ;

Bearden, James D. ;

Saez, Ruben A. ;

Greco, F. Anthony .

CANCER, 2008, 112 (06) :1288-1295

[28] Excess mortality after treatment with fludarabine and cyclophosphamide in combination with alemtuzumab in previously untreated patients with chronic lymphocytic leukemia in a randomized phase 3 trial [J].

Lepretre, Stephane ;

Aurran, Therese ;

Mahe, Beatrice ;

Cazin, Bruno ;

Tournilhac, Olivier ;

Maisonneuve, Herve ;

Casasnovas, Olivier ;

Delmer, Alain ;

Leblond, Veronique ;

Royer, Bruno ;

Corront, Bernadette ;

Chevret, Sylvie ;

Delepine, Roselyne ;

Vaudaux, Sandrine ;

Van den Neste, Eric ;

Bene, Marie Christine ;

Letestu, Remi ;

Cymbalista, Florence ;

Feugier, Pierre .

BLOOD, 2012, 119 (22) :5104-5110

[29] Significant impact of immunosuppression on the incidence of secondary malignancies following fludarabine, cyclophosphamide, and rituximab (FCR) treatment in patients with indolent B-cell neoplasms [J].

Denizon, Nathalie ;

de Materre, Alix Baugier ;

Alani, Mustapha ;

Ghnaya, Habib ;

Farhi, Jonathan ;

Besancon, Anne ;

Laribi, Kamel .

LEUKEMIA & LYMPHOMA, 2018, 59 (11) :2711-2714

[30] Therapy-related acute myeloid leukemia following treatment of lymphoid malignancies [J].

Bertoli, Sarah ;

Sterin, Arthur ;

Tavitian, Suzanne ;

Oberic, Lucie ;

Ysebaert, Loic ;

Bouabdallah, Reda ;

Vergez, Francois ;

Sarry, Audrey ;

Berard, Emilie ;

Huguet, Francoise ;

Laurent, Guy ;

Prebet, Thomas ;

Vey, Norbert ;

Recher, Christian .

ONCOTARGET, 2016, 7 (52) :85937-85947

← 1 2 3 4 5 →